X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims at activation of Washington University School of Medicine as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 (aprepitant) for the treatment for rash and skin disorders associated with EGFR inhibitor therapy.
Lead Product(s): Aprepitant
Therapeutic Area: Dermatology Product Name: HT-001
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2023
Details:
The aim of the collaboration is to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of BL-8040 (motixafortide) to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD).
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Genetic Disease Product Name: BL-8040
Highest Development Status: Phase IProduct Type: Peptide
Recipient: BioLineRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2023
Details:
The collaboration strategically combines Washington University scientists’ expertise in the fundamental and clinical research in neurodegenerative diseases, such as dementia, with Eisai’s extensive experience in drug discovery and development.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2022
Details:
Study finds that tumor behavior specificities linked with patient responses, and the MxIF analyses identified 14 unique cellular neighborhoods in multi-region tumors that can be utilized to optimize treatment strategies for patients with ccRCC.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: BostonGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Ocugen’s intranasal vaccine candidate BBV154, is a recombinant, replication-deficient, adenovirus-vectored vaccine with a prefusion stabilized spike protein. In addition, intranasal delivery provides an alternative to those who are hesitant to receive injectable vaccines.
Lead Product(s): BBV154
Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Ocugen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 28, 2022
Details:
A combination of IMG-7289 (bomedemstat), in solid tumors enhances their immunogenicity, and atezolizumab, a checkpoint inhibitor, represents in lung cancer treatment, may provide long-term disease management possibilities for patients with small cell lung cancer.
Lead Product(s): Bomedemstat,Atezolizumab
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Imago BioSciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
New preclinical authentic ‘live’ virus data demonstrated that EVUSHELD retains potent neutralizing activity against emerging and highly transmissible Omicron SARS-CoV-2 BA.2 subvariant. The data also showed that EVUSHELD retains activity against Omicron BA.1 and BA.1.1.
Lead Product(s): Tixagevimab,Cilgavimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Evusheld
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
This Sponsored Research Agreement with Washington University in St. Louis aims to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of symptoms related to Alzheimer's disease.
Lead Product(s): HT-ALZ
Therapeutic Area: Neurology Product Name: HT-ALZ
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 07, 2021
Details:
UltraPorator system is an exclusive device and proprietary software solution for the scale-up of rapid and cost-effective, decentralized manufacturing of UltraCAR-T therapies.
Lead Product(s): PRGN-3005
Therapeutic Area: Oncology Product Name: PRGN-3005 UltraCAR-T
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Precigen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
This vaccine expands Bharat’s portfolio of vaccines that are currently being developed and are in various stages of clinical development including COVAXIN® which is currently in Phase II human clinical trials in India.
Lead Product(s): Covid 19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bharat Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
